RESEARCH ARTICLE

EVALUATION OF SOME HEMATOLOGICAL AND SEROLOGICAL CHANGES IN DENGUE PATIENTS OF LAHJ-YEMEN

Manal Mohamed AL-Samadi¹ and Khaled Saeed Ali²,*

¹Biology Department, Faculty of Education - Aden, University of Aden, Aden, Yemen
²Pharmaceutical Chemistry, Faculty of Pharmacy - Aden, University of Aden, Aden, Yemen
*Corresponding author: Khaled Saeed Ali E-mail: alsweidi1@gmail.com

Received: 16 Jan 2020 / Accepted: 10 Feb 2020 / Published online: 07 Mar 2020

Abstract

The present study aimed to evaluate the changes in WBC and platelet count and detection of NS1 antigen, IgM and IgG antibodies in dengue patients. There were 103 confirmed cases of dengue including 49(47.6%) females and 54(52.4%) males. The WBC count was less than (2000 /μl) in 16 cases and was ranging between (2000-4000 /μl) in 44 cases. The platelets count decreased to <50000/μl in 4 (3.9%) of cases, <100,000/μl (50,000-100,000/μl) in 14 (13.6%) of cases, and were between (100000-150000/ul) in 12 cases. About 83 (80.6%) patients were positive NS1 antigen, and 4 (3.9%) patients had IgM antibodies against dengue. Remaining 16 (15.5%) had both IgM and IgG antibodies against dengue. The identification of NS1 antigen, WBC and platelet count can be used as predictors of dengue infection.

Keywords: Dengue Fever, serology, WBC count, PLT count.

1. Introduction

Dengue fever (DF) is caused by mosquito-borne single-stranded (RNA) positive-strand Dengue virus (DENV), which has four serotypes of the dengue virus (DEN-1, DEN-2, DEN-3, and DEN-4) also referred to as an arbovirus (arthropod-borne viruses). It belongs to the family Flaviviridae, genus Flavivirus [1-3] and manifests as an acute febrile illness [4,5] in tropical and subtropical areas more than 100 countries and districts displayed dengue endemic [6-8], including Yemen. [9-12]

Transmission to humans occurs by the female bite of the Aedes aegypti mosquito, which infected by four serotypes of the virus. The incubation period of the virus in humans ranges from 3 to 15 days with an average of 5 days following the transmission. [13, 14]

Dengue fever disease characterized by sudden onset of fever of 3-5 days with some symptoms, like intense headache, myalgia, retro-orbital pain, anorexia, gastrointestinal disturbances and rash [15]. Therefore, specific laboratory tests are necessary for an accurate diagnosis.

Thrombocytopenia and leukopenia serve as a predictive marker to promote the early diagnosis of dengue infection. Apart from the dengue-specific parameters, the platelet count is the only accessory laboratory test available in the peripheral areas that can support the diagnosis of DHF or DSS. [5, 16]

The nonstructural proteins are involved in viral translation, transcription, and replication. Among these proteins, an NS1 is involved in viral RNA replication. Notably, NS1 is expressed on the surface of infected cells without forming part of the virion. Serum levels of secreted NS1 (sNS1) positively correlate with viral titers and have been a useful tool in dengue infection diagnosis [17, 18]. The detection of IgM and IgG antibodies are used for diagnosis of dengue, where the most widely used serological techniques for routine treatment of dengue virus infections are the IgM antibody-capture enzyme-linked immunosorbent assay (MAC-ELISA) [19-21]. In the present study, we evaluated the hematological profile of seropositive (IgM) dengue fever patients.

2. Materials and methods

The study carried out with 103 patients diagnosed with dengue, include 54 male (M) and 49 female (F). The case definition was based on the examination of CBC for estimating WBC and platelet count. The detection of (NS1) protein serological test for dengue were done using Dengue Ag Rapid Test and Dengue IgG/IgM Combo Rapid Test. All diagnosis was done at AL-Jamaheer Medical Center, Lahj during the period from July-September 2018.
3. Results and discussion

About 103 patients with dengue fever data were used in this study. Patients got admitted to AL-Jamaheer Medical Center from a different area of Tuban district, Lahej. Figure 1. Shows the resident of the studied cases with dengue fever, the observed a higher percentage of patients with dengue fever were from Bir Nasser area (27.18%), followed by AL-Fayush area (14.56%).

The maximum frequency of dengue fever was in the age group of 20.00 - 30.00 years (33.0%) followed by 21 - 30.00 years (25.2%) and 31 - 40.00 years (15.5%) respectively.

Table (1) indicates the frequency of dengue fever according to age and sex. The age of patients with dengue fever ranged from 1 to 60 years. The female patients from about (47.6%) were slightly lower than male patients (52.4%).

The collected specimens were diagnosed by serological tests to detect NS1antigen and IgM and IgG antibodies against the dengue virus. The serological diagnosis of studied cases result in detecting about 83 (80.6%) patients, who were NS1 antigen positive and 4 (3.9%) patients had IgM antibodies against dengue. Remaining 16 (15.5%) had both IgM and IgG antibodies against dengue (Table 2).

Table (2): Frequency of dengue fever according to a Serological prevalence and Sex.

| Serological | Sex | Total |
|-------------|-----|-------|
|             | F   | m    | N    | %   |
| NS1+        | 43  | 51.8%| 40   | 48.2%| 83  | 80.6% |
| IgM+        | 2   | 50.0%| 2    | 50.0%| 4   | 3.9%  |
| IgM+IgG+    | 4   | 25.0%| 12   | 75.0%| 16  | 15.5% |
| Total       | 49  | 47.6%| 54   | 52.4%| 103 | 100.0%|

Figure (1): Residence of the studied patients with dengue fever.

Dengue NS1 antigen testing is a direct method of dengue virus detection. It used to achieve an early, conclusive, and serotype-specific diagnosis if it has been less than five days since the onset of fever rapidly, and at a lower cost than other methods such as PCR. [22]

Dengue IgM and/or IgG are the tests of choice after the first five days of illness, IgM is detected 5 or more days after the onset of illness in the majority of infected individuals and immunoglobulin IgG is detected from 10–15 days. In secondary infections, IgM appears earlier or in the same time frame but are usually at lower titers than in primary infection. IgG is present from the previous infection and the titer increases rapidly. [20, 23]

The CBC test is one of detecting method used for in dengue patients, we observed the decreasing of WBC (leukopenia) followed by platelets (thrombocytopenia) by the day of the fever, specifically on days 3 to 7 of fever.

As shown in Table (3), among studied 103 cases, 16 cases had a lower total WBC count, were less than (2000 /μl) and the total WBC count of 44 cases was ranging (2000-4000 /μl). The remaining cases had more than (4000/μl). Leukopenia was found from day 3 of fever and the incidence increased on successive days of the fever until day 5 and then there was a gradual recovery.

The platelet count were of <50000/μl in 14 (13.6%) of cases, <100,000/μl (50,000- 100,000/μl) in 14 (13.6%) of cases, and were between (100000-150000/μl) in 12 cases. (Table 4).

The WBCs and platelet count alter each day of the fever in patients infected with dengue. The platelet and WBC counts were found to be predictive as well as recovery parameters of dengue fever [21, 24]. Leucopenia is usually observed in the course of dengue fever. Both DF and DHF patients showed mean values less than 5000/μl [25]. A total leucocyte count of less than 2.6 × 109/L and platelet count less than 100 × 109/L at day 2.5 was highly suggestive of a child progressing into DHF [26]. These findings were similar to our study. According to WHO guidelines, the thrombocytopenia are one of the criteria, that is used as a potential indicator of clinical severity [27, 28]. In the most recent 2009 WHO guidelines, the definitions generally describe a rapid decline in platelet count or a platelet count less than 150,000 per microliter of blood. [29]
Table (4): Frequency of dengue fever according to a platelet cell and Age

| Age   | PLT Count | Total | N (%) | N (%) | N (%) | N (%) | N (%) | N (%) |
|-------|-----------|-------|-------|-------|-------|-------|-------|-------|
| < 10  | (< 2000)  | 6(13.6%) | 7(14.9%) | 13(26.5%) | 13(26.5%) | 29(58.8%) | 35(71.8%) | |
| 10-20 | (2000-300) | 4(8.5%) | 6(12.8%) | 14(28.5%) | 14(28.5%) | 34(68.9%) | 47(94.2%) | |
| 21-30 | (3000-400) | 2(4.1%) | 4(8.3%) | 11(22.4%) | 11(22.4%) | 23(46.2%) | 34(68.3%) | |
| 31-40 | (4000-500) | 2(4.1%) | 3(6.1%) | 9(18.3%) | 9(18.3%) | 20(40.0%) | 29(57.9%) | |
| > 50  | (> 5000)  | 2(4.1%) | 3(6.1%) | 9(18.3%) | 9(18.3%) | 20(40.0%) | 29(57.9%) | |

Table (5): Frequency of dengue fever according to WBC and platelet.

| WBC       | PLT Count / μl | Total | N (%) | N (%) | N (%) | N (%) | N (%) |
|-----------|----------------|-------|-------|-------|-------|-------|-------|
| <5000     | (<100000)      | 18(3.9%) | 14(28.7%) | 73(14.7%) | 73(14.7%) | 141(27.6%) | 133(26.8%) | |
| >5000     | (>100000)      | 12(2.7%) | 17(3.5%) | 86(17.3%) | 86(17.3%) | 103(20.3%) | 103(20.3%) | |

Conclusion

Among 103 cases of dengue, we observed that (14.9%) had DF and the same number (14.9%) also had DHF cases according to classification WHO. In endemic countries can be useful Peripheral blood parameters as thrombocytopenia and leukopenia with serology confirmation in the prediction of prognosis of dengue and thus assessed can be of value for better care of complicated cases.

Acknowledgments

We acknowledge Dr. Fatima Al-Samadi, a teacher in the Department of Mathematics at the University of Abyan, for her help in preparing the statistic for this article.

References

[1] Anderson, C. R., Downs, W. G., Hill, A. E., “Isolation of Dengue Virus from a Human Being in Trinidad,” Science (Washington), Vol.124, pp.224-5, 1956.

[2] Thomas J. Chambers, Chang S. Hahn, Ricardo Galler, and Charles M. Rice, “Flavivirus genome organization, expression, and replication,” Department of Molecular Microbiology, Annual review of microbiology, vol. 44, no. 1, pp. 649-688.

[3] I. A. Rodenhuis-Zybert, J. Wilschut, and J. M. Smit, “Dengue virus life cycle: viral and host factors modulating infectivity,” Cellular and molecular life sciences, vol. 67, no. 16, pp. 2773-2786. 2010.

[4] P. Jyothi and B. C. Metri, “Correlation of serological markers and platelet count in the diagnosis of Dengue virus infection,” Advanced biomedical research, vol. 4, 2015.

[5] V. Sindhanai, S. Banoo, N. Rajkumar and V.C. Sureshchander, “Evaluation of correlation between dengue serological markers & Platelet
count,” Sch J App Med Sci, vol. 4, no. 26, pp. 618-22, 2016.

[6] L. Luo, L.Y. Jiang, X.C. Xiao, B. Di, Q. L. Jing, S. Y. Wang, J. L. Tang, M. Wang, X. P. Tang and Z. C. Yang, “The dengue preface to endemic in mainland China: the historical largest outbreak by Aedes albopictus in Guangzhou, 2014,” Infectious diseases of poverty, vol. 6, no. 1, pp. 148, 2017.

[7] Q. Jing and M. Wang, “Dengue epidemiology,” Global Health Journal, vol. 3 no. 2, pp. 37-45. 2019.

[8] World Health Organization. (2017). Dengue and Severe Dengue—Fact Sheet Updated on April 2017.

[9] “Dengue and malaria update” http://www.emro.who.int/yem/yemen-news/dengue-malaria-update-response.html. Saturday 4th of January 2020 07:11:07 PM.

[10] K. A. Alghazali, B.T. Teoh, S. K. Loong, S. S. Sam, N. A. A. C.M. Seri, N. I. Samsudin, C. N. Yaaeob, N. S. Azizan, A. Oo, N. A. Baharudin, K. K. Tan, J. A. Jamil, S. S. Nor’e, C. S. Khor, J. Johari, M. A.K. Mahdy, S. AbuBakar, “Dengue Outbreak during Ongoing Civil War, Taiz, Yemen,” 2019,” Emerging Infectious Diseases, vol. 6, no. 1, pp. 148, 2017. Vol. 25, No. 7, July 2019.

[11] M. A. Al-Garadi, “Epidemiological review of dengue fever in Yemen,” International Journal of Advanced Research, vol. 3, no. 7, pp. 1578-1584. Vol. 25, No. 7, July 2019.

[12] WHO scales up response to control dengue fever in Yemen. http://www.emro.who.int/eha/news/who-scales-up-response-to-control-dengue-fever-in-yemen.html.

[13] K. Oishi, M. Saito, C. A. Mapua and F. F. Natividad, “Dengue illness: clinical features and pathogenesis,” Journal of infection and chemotherapy, Vol. 13, no. 3, pp. 125-133. June 2007.

[14] C. Lin, S. Wan, H. Cheng, H. Lei and Y. Lin,” Autoimmune pathogenesis in dengue virus infection,” Viral immunology, Vol. 19, no. 2, pp. 127-132. Jul 2006.

[15] K. Park,” Epidemiology of Communicable Diseases: Dengue syndrome,” Park’s textbook of Preventive and Social Medicine. 20th edition, Jabalpur, India: M/s Bhanarsidas Bhanot, pp. 218-22. 2009.

[16] A. Anagha and B. Gayathri,” Hematological parameters in dengue-the serological angle A study,” International Journal of Hematology Research, Vol. 4, no. 1, pp. 180-184. 2018.

[17] F. M. Kassim, M. N. Izati, T. TgRogayah, Y. M. Apandi, and Z. Saat, “Use of dengue NS1 antigen for early diagnosis of dengue virus infection,” Southeast Asian Journal of Tropical Medicine and Public Health, vol. 42, no. 3, pp. 562–569, 2011.

[18] M. da Rocha Queiroz Lima, R. M. R. Nogueira, H. G. Schatzmayr, A. M. B. de Filippis, D. Limonta, and F. B. dos Santos, “A new approach to dengue fatal cases diagnosis: NS1 antigen captur in tissues,” PLoS Neglected Tropical Diseases, vol. 5, no. 5, Article ID e1147, 2011.

[19] R. W. Peeling, H. Artsob, J. L. Pelegrino, P. Buchy, M. J. Cardosa, S. Devi, D. A. Enria, J. Farrar, D. J. Gubler, M. G. Guzman, S. B. Halstead, E. Hunspenger, S. Kliks, H. S. Margolis, C. M. Nathanson, V. C. Nguyen, N. Rizzo, S. Vázquez and S. Yoksan, “Evaluation of Diagnostic Tests: Dengue,” Nature Reviews Microbiology, vol. 8, no. 12, pp.S30-S37, December 2010.

[20] C. Kosack, R. Li, M. Bastard, N. Ford and M. Casenghi, “NS1 antigen detecting assays for diagnosing acute dengue infection in people living in or returning from endemic countries,” The Cochrane database of systematic reviews, no.5. 2018.

[21] Cucunawangsih, N. P. H. Lugito and A. Kurniawan, “Immunoglobulin G (IgG) to IgM ratio in secondary adult dengue infection using samples from early days of symptoms onset,” BMC infectious diseases, vol.15 no. 1, pp. 276. 2015.

[22] H. B.Y. Chan, C.H. How and C. W. M. Ng, “Definitive tests for dengue fever: when and which should I use?,” Singapore medical journal, vol. 58 no.11, pp. 632. 2017.
Evaluation of Some Hematological and Serological Changes in Dengue Patients of Lahj-Yemen

[23] World Health Organization, Special Programme for Research, Training in Tropical Diseases, World Health Organization. Department of Control of Neglected Tropical Diseases, World Health Organization. Epidemic, & Pandemic Alert. (2009). Dengue: guidelines for diagnosis, treatment, prevention and control. World Health Organization.

[24] A. M. Lakal and K. S. Ali, “White blood cells and Platelets as Predictive Parameters in Dengue Fever,” World Journal of Pharmaceutical Research, vol.7, no.17, pp. 239-243. Sept. 2018.

[25] U. Ralapanawa, A. T. M. Alawattegama, M. Gunaratne, S. Tennakoon, S. A. M. Kularatne and T. Jayalath,” Value of peripheral blood count for dengue severity prediction,” BMC research notes, vol. 11, no.1, pp. 400, Jun. 2018.

[26] G. A. M. Kularatnam, E. A. Jas inghe, S. Gunasena, D. Samaranayake, M. P. Senanayake, V. P. Wickramasinghe,” Evaluation of Biochemical Changes in Dengue Fever and Dengue Haemorrhagic Fever,” Paper presented at the 17th Annual Scientific Congress of the Sri Lanka College of Paediatricians, pp.26-29, July. 2014.

[27] N. Sharma, K. P. Mishra, S. Chanda, V. Bhardwaj, H. Tanwar, L. Ganju, B. Kumar and S. B. Singh,” Evaluation of anti-dengue activity of Carica papaya aqueous leaf extract and its role in platelet augmentation”, Archives of virology, vol. 164, no. 4, pp. 1095-1110, 2019.

[28] R. K. Khare and P. Raj,” Dengue fever with Thrombocytopenia and its complications: A hospital based study,” Journal of Advanced Medical and Dental Sciences Research, vol. 5, no. 3, pp.72, 2017.

[29] E. L. d. Azeredo, R. Q. Monteiro, and L. M. d. O. Pinto,” Thrombocytopenia in dengue: interrelationship between virus and the imbalance between coagulation and fibrinolysis and inflammatory mediators,” Mediators of inflammation, Volume 2015 |Article ID 313842 | 16 pages.

[30] World Health Organization,” Comprehensive guideline for prevention and control of dengue and dengue haemorrhagic fever,” 2011.